Sofinnova Partners SAS - Jan 6, 2022 Form 3 Insider Report for CinCor Pharma, Inc. (CINC)

Role
10%+ Owner
Signature
Sofinnova Partners SAS, By Monique Saulnier, Managing Partner
Stock symbol
CINC
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
3
Date filed
1/6/2022, 07:56 PM
Next filing
Jan 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CINC Series A Preferred Stock Jan 6, 2022 Common Stock 2.94M By Sofinnova Capital IX F1, F2
holding CINC Series B Preferred Stock Jan 6, 2022 Common Stock 926K By Sofinnova Capital IX F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F2 The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.